Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,824,269
  • Shares Outstanding, K 108,201
  • Annual Sales, $ 509,340 K
  • Annual Income, $ -207,040 K
  • EBIT $ -159 M
  • EBITDA $ -171 M
  • 60-Month Beta 0.71
  • Price/Sales 3.50
  • Price/Cash Flow N/A
  • Price/Book 4.94

Options Overview Details

View History
  • Implied Volatility 92.22% ( -5.75%)
  • Historical Volatility 70.29%
  • IV Percentile 92%
  • IV Rank 43.53%
  • IV High 139.14% on 03/25/24
  • IV Low 56.05% on 05/09/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 163
  • Volume Avg (30-Day) 949
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 38,490
  • Open Int (30-Day) 39,118

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.41
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.10 +10.93%
on 11/01/24
18.67 -10.28%
on 11/08/24
+0.48 (+2.95%)
since 10/21/24
3-Month
14.17 +18.21%
on 10/08/24
21.82 -23.22%
on 10/16/24
-0.75 (-4.29%)
since 08/21/24
52-Week
11.29 +48.36%
on 11/28/23
24.74 -32.28%
on 05/20/24
+4.52 (+36.96%)
since 11/21/23

Most Recent Stories

More News
NovoCure (NVCR) Q3 2024 Earnings Call Transcript

NVCR earnings call for the period ending September 30, 2024.

NVCR : 17.06 (+1.19%)
NovoCure: Q3 Earnings Snapshot

NovoCure: Q3 Earnings Snapshot

NVCR : 17.06 (+1.19%)
Stocks Mixed on Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.48%. Stocks today are mixed....

UAL : 94.00 (-0.67%)
SYF : 65.25 (+1.32%)
UHS : 197.16 (-0.18%)
IBKR : 192.01 (+2.21%)
ULTA : 336.21 (-2.05%)
CSCO : 57.68 (+0.31%)
CFG : 47.05 (+2.02%)
USB : 51.88 (+2.25%)
$SPX : 5,957.71 (+0.69%)
MS : 135.19 (+2.66%)
JBHT : 181.85 (+0.15%)
EL : 66.93 (+2.45%)
Stock Index Futures Steady After Yesterday’s Sell-Off, Earnings in Focus

December S&P 500 E-Mini futures (ESZ24) are up +0.03%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.08% this morning, steadying after yesterday’s slump, while investors awaited the next round...

KLAC : 637.50 (+3.35%)
AA : 46.35 (+1.33%)
NVDA : 146.65 (+0.52%)
IBKR : 192.01 (+2.21%)
CSCO : 57.68 (+0.31%)
USB : 51.88 (+2.25%)
MS : 135.19 (+2.66%)
KMI : 28.53 (+1.89%)
JBHT : 181.85 (+0.15%)
EL : 66.93 (+2.45%)
NQZ24 : 20,864.25 (+0.56%)
PLD : 114.54 (+0.14%)
Why NovoCure Stock Dived by 13% This Week

Investors found the announced changes to the company's C-suite unsettling.

NVCR : 17.06 (+1.19%)
Chips, Glorious Chips!

Someone's gotta make 'em, and someone's gotta buy 'em.

AMD : 137.46 (-0.10%)
NVDA : 146.65 (+0.52%)
META : 561.78 (-0.66%)
MSFT : 414.35 (-0.07%)
GOOGL : 166.49 (-5.39%)
AMZN : 198.46 (-2.18%)
INTC : 24.69 (+2.83%)
ISRG : 549.84 (+1.48%)
DXCM : 75.31 (+0.09%)
GOOG : 168.01 (-5.26%)
PODD : 263.28 (-1.24%)
TNDM : 31.14 (+3.28%)
NovoCure (NVCR) Q2 2024 Earnings Call Transcript

NVCR earnings call for the period ending June 30, 2024.

NVCR : 17.06 (+1.19%)
NovoCure: Q2 Earnings Snapshot

NovoCure: Q2 Earnings Snapshot

NVCR : 17.06 (+1.19%)
NovoCure (NVCR) Q1 2024 Earnings Call Transcript

NVCR earnings call for the period ending March 31, 2024.

NVCR : 17.06 (+1.19%)
NovoCure: Q1 Earnings Snapshot

NovoCure: Q1 Earnings Snapshot

NVCR : 17.06 (+1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 18.53
2nd Resistance Point 17.94
1st Resistance Point 17.40
Last Price 17.06
1st Support Level 16.27
2nd Support Level 15.68
3rd Support Level 15.14

See More

52-Week High 24.74
Fibonacci 61.8% 19.60
Fibonacci 50% 18.01
Last Price 17.06
Fibonacci 38.2% 16.43
52-Week Low 11.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar